DaVita Inc. (NYSE:DVA) Receives $161.80 Consensus Target Price from Brokerages

DaVita Inc. (NYSE:DVA - Get Free Report) has been given an average recommendation of "Hold" by the five analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $161.80.

DVA has been the subject of several recent analyst reports. Truist Financial upped their target price on shares of DaVita from $165.00 to $175.00 and gave the stock a "hold" rating in a research note on Monday, October 7th. UBS Group boosted their target price on DaVita from $169.00 to $175.00 and gave the stock a "buy" rating in a research note on Thursday, August 8th. Bank of America lifted their price target on DaVita from $139.00 to $145.00 and gave the stock an "underperform" rating in a report on Wednesday, August 7th. Barclays lifted their target price on DaVita from $150.00 to $164.00 and gave the stock an "equal weight" rating in a research note on Thursday. Finally, TD Cowen increased their target price on shares of DaVita from $139.00 to $150.00 and gave the company a "hold" rating in a research report on Wednesday, July 24th.

DaVita Stock Up 1.3 %

NYSE DVA traded up $1.82 during mid-day trading on Friday, hitting $141.63. The company's stock had a trading volume of 506,224 shares, compared to its average volume of 817,422. DaVita has a twelve month low of $76.64 and a twelve month high of $168.50. The firm has a market capitalization of $11.61 billion, a price-to-earnings ratio of 15.08, a PEG ratio of 0.82 and a beta of 0.87. The company's 50 day simple moving average is $157.96 and its 200 day simple moving average is $145.97. The company has a current ratio of 1.37, a quick ratio of 1.12 and a debt-to-equity ratio of 15.78.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing analysts' consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. During the same period in the prior year, the firm posted $2.85 earnings per share. The business's revenue for the quarter was up 4.6% on a year-over-year basis. Analysts anticipate that DaVita will post 9.84 earnings per share for the current year.

Insider Activity

In related news, insider Kathleen Alyce Waters sold 7,857 shares of DaVita stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the sale, the insider now owns 83,011 shares of the company's stock, valued at approximately $12,137,038.31. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other DaVita news, CEO Javier Rodriguez sold 50,000 shares of the company's stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the sale, the chief executive officer now directly owns 837,835 shares in the company, valued at $138,284,666.75. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Kathleen Alyce Waters sold 7,857 shares of the firm's stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the sale, the insider now directly owns 83,011 shares in the company, valued at approximately $12,137,038.31. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 173,482 shares of company stock worth $27,387,069. 2.00% of the stock is owned by company insiders.

Institutional Trading of DaVita

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in shares of DaVita by 1.6% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 134,823 shares of the company's stock worth $18,612,000 after acquiring an additional 2,129 shares during the period. First Trust Direct Indexing L.P. lifted its holdings in shares of DaVita by 3.9% during the first quarter. First Trust Direct Indexing L.P. now owns 2,590 shares of the company's stock valued at $358,000 after purchasing an additional 98 shares during the last quarter. Janney Montgomery Scott LLC boosted its position in shares of DaVita by 175.5% in the 1st quarter. Janney Montgomery Scott LLC now owns 18,937 shares of the company's stock worth $2,614,000 after purchasing an additional 12,064 shares in the last quarter. Hussman Strategic Advisors Inc. bought a new stake in DaVita in the first quarter worth $2,899,000. Finally, Tokio Marine Asset Management Co. Ltd. grew its stake in shares of DaVita by 11.9% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 2,377 shares of the company's stock worth $328,000 after acquiring an additional 253 shares during the period. Hedge funds and other institutional investors own 90.12% of the company's stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.